ivermectin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antiparasitics, ivermectin derivatives 3972 70288-86-7

Description:

MoleculeDescription

Synonyms:

  • ivermectin
  • noramectin
  • noromectin
  • zimecterin
A mixture of mostly avermectin H2B1a (RN 71827-03-7) with some avermectin H2B1b (RN 70209-81-3), which are macrolides from STREPTOMYCES avermitilis. It binds glutamate-gated chloride channel to cause increased permeability and hyperpolarization of nerve and muscle cells. It also interacts with other CHLORIDE CHANNELS. It is a broad spectrum antiparasitic that is active against microfilariae of ONCHOCERCA VOLVULUS but not the adult form. In vitro data suggest evidence of activity against SARS-CoV-2, but to date available data are insufficient to recommend either for or against the use of ivermectin for the treatment of COVID-19. FDA issued a warning concerning possi-ble inappropriate use of ivermectin products intended for animals as an attempt to self-medicate for the treat-ment of COVID-19.
  • Molecular weight: 1736.19
  • Formula: C95H146O28
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
12 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 4 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.17 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Nov. 22, 1996 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Conjunctival haemorrhage 269.77 23.55 60 5592 3924 90618871
Ocular hyperaemia 163.78 23.55 66 5586 33732 90589063
Vertigo 140.43 23.55 74 5578 69737 90553058
Asthenia 135.60 23.55 166 5486 533585 90089210
Headache 133.36 23.55 211 5441 862535 89760260
Malaria 111.85 23.55 18 5634 195 90622600
Somatic delusion 92.82 23.55 18 5634 596 90622199
Product use in unapproved indication 82.51 23.55 103 5549 336133 90286662
Coma 77.20 23.55 51 5601 72581 90550214
Skin irritation 70.82 23.55 28 5624 13575 90609220
Encephalopathy 62.82 23.55 38 5614 46406 90576389
Pyrexia 60.15 23.55 129 5523 660356 89962439
Logorrhoea 56.90 23.55 16 5636 2711 90620084
Methaemoglobinaemia 54.98 23.55 17 5635 3998 90618797
Abnormal faeces 54.02 23.55 19 5633 6663 90616132
Gastrointestinal motility disorder 51.86 23.55 18 5634 6073 90616722
Depressed level of consciousness 51.70 23.55 40 5612 72744 90550051
Mixed liver injury 51.58 23.55 19 5633 7604 90615191
Urine odour abnormal 48.81 23.55 18 5634 7226 90615569
Erythema 47.96 23.55 65 5587 229181 90393614
Skin burning sensation 45.75 23.55 23 5629 19588 90603207
Oral discomfort 45.70 23.55 19 5633 10464 90612331
Off label use 44.66 23.55 160 5492 1102092 89520703
Mazzotti reaction 43.42 23.55 5 5647 0 90622795
Urinary incontinence 41.40 23.55 27 5625 37539 90585256
Product prescribing issue 40.05 23.55 16 5636 7963 90614832
Chromaturia 37.55 23.55 20 5632 19167 90603628
Strongyloidiasis 36.17 23.55 10 5642 1592 90621203
Dermatitis contact 34.84 23.55 17 5635 13578 90609217
Acute generalised exanthematous pustulosis 34.71 23.55 17 5635 13686 90609109
Hepatic cytolysis 33.52 23.55 22 5630 30894 90591901
Musculoskeletal discomfort 33.16 23.55 19 5633 20972 90601823
Acarodermatitis 32.90 23.55 9 5643 1377 90621418
Hepatocellular injury 32.36 23.55 21 5631 28937 90593858
Pruritus 31.29 23.55 89 5563 541436 90081359
Rash papular 31.03 23.55 18 5634 20337 90602458
Visceral larva migrans 29.19 23.55 4 5648 12 90622783
Congenital muscle absence 27.40 23.55 4 5648 21 90622774
Language disorder 27.14 23.55 9 5643 2643 90620152
Aphasia 27.10 23.55 22 5630 42790 90580005
Rosacea 26.85 23.55 11 5641 5836 90616959
Abnormal behaviour 26.74 23.55 17 5635 22611 90600184
Vascular purpura 26.53 23.55 8 5644 1730 90621065
Nematodiasis 25.84 23.55 4 5648 33 90622762
Agitation 25.72 23.55 26 5626 67072 90555723
Cheilitis 24.99 23.55 10 5642 4997 90617798

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Conjunctival haemorrhage 846.75 26.72 179 6942 3354 42610860
Ocular hyperaemia 566.15 26.72 176 6945 15787 42598427
Asthenia 446.42 26.72 369 6752 280424 42333790
Headache 440.69 26.72 343 6778 239026 42375188
Coma 392.62 26.72 187 6934 53367 42560847
Vertigo 260.70 26.72 123 6998 34224 42579990
Pyrexia 234.12 26.72 306 6815 393736 42220478
Urinary incontinence 232.81 26.72 99 7022 21569 42592645
Malaria 226.24 26.72 38 7083 180 42614034
Encephalopathy 158.87 26.72 94 7027 41239 42572975
Back pain 144.27 26.72 146 6975 141630 42472584
Gait disturbance 130.17 26.72 117 7004 97883 42516331
Depressed level of consciousness 94.37 26.72 72 7049 47898 42566316
Product use in unapproved indication 90.10 26.72 131 6990 184325 42429889
Abnormal behaviour 85.75 26.72 54 7067 26397 42587817
Language disorder 78.01 26.72 25 7096 2450 42611764
Strongyloidiasis 73.80 26.72 26 7095 3405 42610809
Myalgia 64.83 26.72 80 7041 96000 42518214
Nuchal rigidity 61.92 26.72 15 7106 521 42613693
Disseminated strongyloidiasis 57.07 26.72 14 7107 513 42613701
Logorrhoea 55.55 26.72 20 7101 2787 42611427
Filariasis 53.88 26.72 7 7114 0 42614214
Rhinocerebral mucormycosis 53.32 26.72 14 7107 676 42613538
Adverse event 52.06 26.72 38 7083 23602 42590612
Arthralgia 51.74 26.72 109 7012 205129 42409085
Anal incontinence 48.64 26.72 26 7095 9355 42604859
Blood smear test abnormal 46.19 26.72 6 7115 0 42614214
Stupor 46.11 26.72 18 7103 3135 42611079
Pruritus 46.11 26.72 99 7022 188672 42425542
Chills 38.96 26.72 62 7059 94004 42520210
Decubitus ulcer 30.49 26.72 20 7101 10457 42603757
Speech disorder 29.48 26.72 30 7091 29091 42585123
Haemophagocytic lymphohistiocytosis 28.63 26.72 24 7097 18198 42596016
Eyelid oedema 27.33 26.72 15 7106 5680 42608534
Neck pain 26.95 26.72 29 7092 29985 42584229

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Conjunctival haemorrhage 1113.19 21.19 233 11948 6400 110570718
Ocular hyperaemia 698.25 21.19 232 11949 39054 110538064
Asthenia 560.98 21.19 518 11663 688481 109888637
Coma 454.75 21.19 233 11948 117636 110459482
Headache 453.38 21.19 518 11663 881859 109695259
Vertigo 382.74 21.19 188 11993 86682 110490436
Malaria 340.78 21.19 56 12125 371 110576747
Pyrexia 291.93 21.19 421 11760 897844 109679274
Urinary incontinence 268.50 21.19 123 12058 48464 110528654
Encephalopathy 230.41 21.19 131 12050 80924 110496194
Product use in unapproved indication 144.77 21.19 210 11971 447167 110129951
Depressed level of consciousness 143.16 21.19 110 12071 112168 110464950
Back pain 134.57 21.19 184 11997 370812 110206306
Abnormal behaviour 132.57 21.19 71 12110 38968 110538150
Strongyloidiasis 123.61 21.19 38 12143 4948 110572170
Language disorder 115.64 21.19 34 12147 3804 110573314
Gait disturbance 114.70 21.19 147 12034 278061 110299057
Logorrhoea 111.21 21.19 35 12146 4922 110572196
Somatic delusion 85.17 21.19 19 12162 702 110576416
Myalgia 75.53 21.19 107 12074 222274 110354844
Disseminated strongyloidiasis 71.67 21.19 16 12165 593 110576525
Nuchal rigidity 70.13 21.19 18 12163 1214 110575904
Rhinocerebral mucormycosis 66.41 21.19 18 12163 1499 110575619
Pruritus 59.47 21.19 169 12012 581391 109995727
Filariasis 56.80 21.19 7 12174 0 110577118
Agitation 56.64 21.19 66 12115 112985 110464133
Anal incontinence 55.69 21.19 33 12148 21931 110555187
Hepatic cytolysis 53.34 21.19 46 12135 55007 110522111
Chills 49.52 21.19 81 12100 190499 110386619
Stupor 49.00 21.19 22 12159 8243 110568875
Mazzotti reaction 48.68 21.19 6 12175 0 110577118
Aphasia 44.81 21.19 43 12138 58954 110518164
Multiple organ dysfunction syndrome 44.26 21.19 68 12113 151642 110425476
Eyelid oedema 44.19 21.19 25 12156 15237 110561881
Methaemoglobinaemia 43.76 21.19 21 12160 9147 110567971
Eosinophilia 41.70 21.19 41 12140 57895 110519223
Mixed liver injury 41.07 21.19 22 12159 12057 110565061
Loss of consciousness 40.02 21.19 75 12106 196231 110380887
Gastrointestinal motility disorder 38.83 21.19 18 12163 7258 110569860
Urine odour abnormal 38.50 21.19 18 12163 7397 110569721
Blood smear test abnormal 37.77 21.19 6 12175 31 110577087
Product prescribing issue 37.19 21.19 21 12160 12751 110564367
Dysstasia 36.99 21.19 30 12151 32956 110544162
Speech disorder 36.05 21.19 39 12142 61530 110515588
Decubitus ulcer 35.10 21.19 23 12158 18213 110558905
Off label use 35.09 21.19 283 11898 1499902 109077216
Abnormal faeces 34.75 21.19 18 12163 9218 110567900
Oral discomfort 34.03 21.19 19 12162 11292 110565826
Haemophagocytic lymphohistiocytosis 33.92 21.19 28 12153 31531 110545587
Nervous system disorder 33.79 21.19 28 12153 31693 110545425
Acarodermatitis 32.35 21.19 11 12170 1970 110575148
Drug reaction with eosinophilia and systemic symptoms 31.59 21.19 42 12139 82053 110495065
Hepatocellular injury 31.27 21.19 33 12148 50609 110526509
Weight increased 30.17 21.19 5 12176 419639 110157479
Disorientation 30.07 21.19 38 12143 70633 110506485
Skin burning sensation 29.13 21.19 22 12159 21803 110555315
Self-medication 28.91 21.19 14 12167 6218 110570900
Adverse event 27.90 21.19 46 12135 108763 110468355
Fatigue 27.63 21.19 58 12123 1215900 109361218
Skin irritation 27.61 21.19 19 12162 16300 110560818
Visceral larva migrans 26.91 21.19 4 12177 12 110577106
Conjunctival hyperaemia 26.75 21.19 13 12168 5818 110571300
Stevens-Johnson syndrome 26.22 21.19 29 12152 46872 110530246
Diarrhoea 26.02 21.19 214 11967 1139291 109437827
Paresis 25.90 21.19 12 12169 4832 110572286
Congenital muscle absence 24.68 21.19 4 12177 24 110577094
Drug ineffective for unapproved indication 24.41 21.19 42 12139 102796 110474322
Drug hypersensitivity 23.99 21.19 10 12171 454080 110123038
Nematodiasis 23.56 21.19 4 12177 33 110577085
Chromaturia 23.43 21.19 22 12159 29338 110547780
Drug effective for unapproved indication 22.81 21.19 16 12165 14151 110562967
Fall 22.54 21.19 20 12161 603462 109973656
Rosacea 22.01 21.19 11 12170 5225 110571893
Musculoskeletal discomfort 21.45 21.19 19 12162 23519 110553599

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D11AX22 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Other dermatologicals
ATC P02CA53 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTHELMINTICS
ANTINEMATODAL AGENTS
Benzimidazole derivatives
ATC P02CF01 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTHELMINTICS
ANTINEMATODAL AGENTS
Avermectines
FDA EPC N0000175484 Antiparasitic
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D007306 Insecticides
MeSH PA D010575 Pesticides
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:24852 insecticide
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35443 anthelminthic drug
CHEBI has role CHEBI:35444 antinematodal drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35820 antiprotozoal drug
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:70868 antileishmanial agent
CHEBI has role CHEBI:73333 scabicide
FDA EPC N0000181811 Pediculicide

Related Drugs by ATC class:

D11AX Other dermatologicals 20 drugs
aminobenzoic acidbrimonidinecaffeinecalcium gluconatedeoxycholic aciddiclofenaceflornithinefinasteridegamolenic acidhydrogen peroxidehydroquinonelithium succinate show all 20 →
P02CA Benzimidazole derivatives 6 drugs
albendazoleciclobendazolefenbendazoleflubendazolemebendazolethiabendazole

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection by Strongyloides indication 1214006 DOID:10955
Infection by Onchocerca volvulus indication 38539003 DOID:11678
Infection by Loa loa contraindication 44250009 DOID:13523
Liver function tests abnormal contraindication 166603001




🐶 Veterinary Drug Use

SpeciesUseRelation
Bison Treatment and control of grubs, Hypoderma bovis Indication
Cats Prevents heartworm disease Indication
Cats Removal and control of adult and immature (L4) hookworms, Ancylostoma tubaeforme Indication
Cats Removal and control of adult and immature (L4) hookworms, A braziliense Indication
Cats Treatment of adult ear mite (Otodectes cynotis) Indication
Cattle Treatment and control of gastrointestinal nematodes, Haemonchus placei (adults and fourth-stage larvae) Indication
Cattle Treatment and control of gastrointestinal nematodes, Ostertagia ostertagi (adults and fourth-stage larvae) Indication
Cattle Treatment and control of gastrointestinal nematodes, O lyrata (adults and fourth-stage larvae) Indication
Cattle Treatment and control of gastrointestinal nematodes, Trichostrongylus axei (adults and fourth-stage larvae) Indication
Cattle Treatment and control of gastrointestinal nematodes, T colubriformis (adults and fourth-stage larvae) Indication
Cattle Treatment and control of gastrointestinal nematodes, Cooperia oncophora (adults and fourth-stage larvae) Indication
Cattle Treatment and control of gastrointestinal nematodes, C punctata (adults and fourth-stage larvae) Indication
Cattle Treatment and control of gastrointestinal nematodes, C pectinata (adults and fourth-stage larvae) Indication
Cattle Treatment and control of gastrointestinal nematodes, Oesophagostomum radiatum (adults and fourth-stage larvae) Indication
Cattle Treatment and control of gastrointestinal nematodes, Nematodirus helvetianus (adults) Indication
Cattle Treatment and control of gastrointestinal nematodes, N spathiger (adults) Indication
Cattle Treatment and control of gastrointestinal nematodes, Bunostomum phlebotomum (adults and fourth-stage larvae) Indication
Cattle Treatment and control of lungworms, Dictyocaulus viviparus, (adult and L4) Indication
Cattle Treatment and control of grubs, Hypoderma bovis Indication
Cattle Treatment and control of grubs, H lineatum Indication
Cattle Treatment and control of sucking lice, Linognathus vituli Indication
Cattle Treatment and control of sucking lice Haematopinus eurysternus Indication
Cattle Treatment and control of sucking lice, Solenopotes capillatus Indication
Cattle Treatment and control of mites, Psoroptes ovis Indication
Cattle Treatment and control of mites, Sarcoptes scabiei var bovis Indication
Cattle Protection (28 days) from reinfection with D viviparus Indication
Cattle Protection (28 days) from reinfection with O radiatum Indication
Cattle Protection (21 days) from reinfection with O ostertagi Indication
Cattle Protection (21 days) from reinfection with T axei Indication
Cattle Protection (21 days) from reinfection with C punctata Indication
Cattle Protection (14 days) from reinfection with H placei Indication
Cattle Protection (14 days) from reinfection with C oncophora Indication
Cervidae Treatment and control of warbles, Oedemagena tarandi Indication
Dogs Prevention of heartworm disease Indication
Foxes Ear mite (Otodectes cynotis) infestations Indication
Horses Treatment and control of large strongyles, Strongylus vulgaris (adults) Indication
Horses Treatment and control of large strongyles, S edentatus (adults) Indication
Horses Treatment and control of large strongyles, S equinus Indication
Horses Treatment and control of large strongyles, Triodontophorus spp (adults) Indication
Horses Treatment and control of large strongyles, Craterostomum acuticaudatum (adults) Indication
Horses Treatment and control of small strongyles, Coronocyclus spp (adults) Indication
Horses Treatment and control of small strongyles, Cyathostomum spp (adults) Indication
Horses Treatment and control of small strongyles, Cylicocyclus spp (adults) Indication
Horses Treatment and control of small strongyles, Cylicodontophorus spp (adults) Indication
Horses Treatment and control of small strongyles, Cylicostephanus spp (adults) Indication
Horses Treatment and control of small strongyles, Petrovinema poculatum (adults) Indication
Horses Indication
Horses Treatment and control of small strongyles, (fourth-stage larvae) Indication
Horses Treatment and control of pinworms Oxyuris equi (adults and fourth stage larvae) Indication
Horses Treatment and control of ascarids (adults and third- and fourth-stage larvae) Parascaris equorum Indication
Horses Treatment and control of Hairworms, Trichostrongylus axei (adults) Indication
Horses Treatment and control of Large mouth Stomach Worms, Habronema muscae (adults) Indication
Horses Treatment and control of bots, (oral and gastric stages) Gasterophilus spp Indication
Horses Treatment and control of Lungworms, Dictyocaulus arnfieldi (adults and fourth-stage larvae) Indication
Horses Treatment and control of Intestinal Threadworms, Strongyloides westeri (adults) Indication
Horses Summer sores caused by Habronema Indication
Horses Summer sores caused by Draschia spp cutaneous third-stage larvae Indication
Horses Dermatitis caused by neck threadworm microfilariae, Onchocerca sp Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Haemonchus contortus Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, H placei (adults only) Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Ostertagia circumcincta Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Trichostrongylus axei Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, T colubriformis Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Cooperia oncophora (adults only) Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, C curticei Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Oesophagostomum columbianum Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, O venulosum (adults only) Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Nematodirus battus Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, N spathiger Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, S papillosus (adults only) Indication
Sheep Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Chabertia ovina (adult only) Indication
Sheep Treatment and control of the gastrointestinal roundworms, Trichuris ovis (adults only) Indication
Sheep Treatment and control of the nasal bot, Oestrus ovis Indication
Sheep Treatment and control of lungworms, D filaria Indication
Swine Treatment and control of gastrointestinal roundworms, Ascaris suum (adults and fourth-stage larvae) Indication
Swine Treatment and control of gastrointestinal roundworms, Ascarops strongylina (adults) Indication
Swine Treatment and control of gastrointestinal roundworms, Hyostrongylus rubidus (adults and fourth-stage larvae) Indication
Swine Treatment and control of gastrointestinal roundworms, Oesophagostomum species (adults and fourth-stage larvae) Indication
Swine Treatment and control of kidneyworms, Stephanurus dentatus (adults and fourth-stage larvae) Indication
Swine Treatment and control of lungworms, Metastrongylus species (adults) Indication
Swine Treatment and control of lice, Haematopinus suis Indication
Swine Treatment and control of mange mites, Sarcoptes scabiei var suis Indication

🐶 Veterinary products

ProductApplicantIngredients
Eqvalan Injection Boehringer lngelheim Animal Health USA Inc. 1
Ivomec .27% Injection Grower And Feeder Pigs, Ivomec 1% Injection, Ivomec 1% Injection for Cattle And Swine, Ivomec Injection for Cattle Boehringer lngelheim Animal Health USA Inc. 1
Ivomec Liquid Boehringer lngelheim Animal Health USA Inc. 1
EQVALAN Boehringer lngelheim Animal Health USA Inc. 1
Ivomec Cattle Paste 0.153% Boehringer lngelheim Animal Health USA Inc. 1
Heartgard 30, Heartgard Tablets Boehringer lngelheim Animal Health USA Inc. 1
Eqvalan Oral Liquid For Horses Boehringer lngelheim Animal Health USA Inc. 1
Ivomec Plus Injection For Cattle Boehringer lngelheim Animal Health USA Inc. 2
Ivomec Pour-On Boehringer lngelheim Animal Health USA Inc. 1
Heartgard Chewables For Dogs Boehringer lngelheim Animal Health USA Inc. 1
Heartgard Plus Boehringer lngelheim Animal Health USA Inc. 2
Ivomec Premix for Swine Boehringer lngelheim Animal Health USA Inc. 1
Ivomec Sustained-Release Bolus for Cattle Boehringer lngelheim Animal Health USA Inc. 1
Heartgard for Cats Boehringer lngelheim Animal Health USA Inc. 1
BMD / Ivomec Premix for Swine Boehringer lngelheim Animal Health USA Inc. 2
Acarexx Boehringer lngelheim Animal Health USA Inc. 1
Advantage DUO Elanco US Inc. 2
ZIMECTERIN Gold Paste Boehringer lngelheim Animal Health USA Inc. 2
Equimax Virbac AH Inc. 2
Zimecterin-EZ Farnam Companies Inc. 1
Iverhart Max Virbac AH Inc. 3
Panacur Plus Intervet Inc. 3
Duocare Boehringer lngelheim Animal Health USA Inc. 2
IVERHART MAX Chew Virbac AH Inc. 3
Phoenectin Elanco US Inc. 1
Ivermectin Pour-On for Cattle, Phoenectin, Phoenectin, Phoenectin Pour-On for Cattle Huvepharma EOOD 1
Phoenectin Huvepharma EOOD 1
Iverhart Tablets Virbac AH Inc. 1
Noromectin Pour-On for Cattle Norbrook Laboratories, Ltd. 1
Phoenectin Paste 1.87% Elanco US Inc. 1
Iversol Liquid for Horses Med-Pharmex Inc. 1
Ivermectin Chewable Tablets Cronus Pharma Specialities India Private Limited 1
Iver-On Med-Pharmex Inc. 1
Iverhart Plus Flavored Chewables Virbac AH Inc. 2
Bimectin Pour-On Bimeda Animal Health Limited 1
Equell Virbac AH Inc. 1
Primectin Equine Oral Liquid First Priority Inc. 1
Bimectin Bimeda Animal Health Limited 1
Privermectin Drench for Sheep First Priority Inc. 1
Tri-Heart Plus Chewable Tablets Heska Corp. 2
Privermectin First Priority Inc. 1
SparMectin-E Sparhawk Laboratories Inc. 1
Ecomectin Huvepharma EOOD 1
Ivermectin Paste 1.87 % Med-Pharmex Inc. 1
Ivermectin Injection Sparhawk Laboratories Inc. 1
Normectin Plus Norbrook Laboratories, Ltd. 2
Noromectin Norbrook Laboratories, Ltd. 1
Bimectin Injection for Cattle and Swine Bimeda Animal Health Limited 1
Bimectin Plus Bimeda Animal Health Limited 2
SparMectin Plus Clorsulon Sparhawk Laboratories Inc. 2
Animec Plus Chanelle Pharmaceuticals Manufacturing Ltd. 1
Ivermectin Paste 1.87% Boehringer lngelheim Animal Health USA Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1% SOOLANTRA GALDERMA LABS LP N206255 Dec. 19, 2014 RX CREAM TOPICAL 10206939 March 13, 2034 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA
1% SOOLANTRA GALDERMA LABS LP N206255 Dec. 19, 2014 RX CREAM TOPICAL 9089587 March 13, 2034 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA
1% SOOLANTRA GALDERMA LABS LP N206255 Dec. 19, 2014 RX CREAM TOPICAL 9233117 March 13, 2034 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA
1% SOOLANTRA GALDERMA LABS LP N206255 Dec. 19, 2014 RX CREAM TOPICAL 9233118 March 13, 2034 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA
1% SOOLANTRA GALDERMA LABS LP N206255 Dec. 19, 2014 RX CREAM TOPICAL 9782425 March 13, 2034 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Multidrug resistance protein 1 Transporter IC50 7 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.41 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.13 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 5.92 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 5.89 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 5.59 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 6.24 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.45 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 6.54 DRUG MATRIX
Neuronal acetylcholine receptor subunit alpha-7 Ion channel ALLOSTERIC MODULATOR EC50 5.10 IUPHAR
Bile acid receptor Nuclear hormone receptor IC50 6.59 CHEMBL
Glycine Receptor Ion channel AGONIST EC50 6.40 IUPHAR
D(1A) dopamine receptor GPCR Ki 5.65 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 5.66 DRUG MATRIX
Glutamate-gated chloride channel Ion channel MODULATOR CHEMBL CHEMBL
Glutamate-gated chloride channel Ion channel MODULATOR CHEMBL CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Enzyme IC50 5.17 CHEMBL
Sodium/potassium-transporting ATPase subunit alpha-1 Enzyme IC50 5.08 CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Enzyme IC50 4.77 CHEMBL
P2X purinoceptor 4 Ion channel ALLOSTERIC MODULATOR EC50 6.60 IUPHAR
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Enzyme IC50 4.82 CHEMBL
Genome polyprotein [Cleaved into: Capsid protein C Enzyme Ki 4.10 CHEMBL

External reference:

IDSource
4021046 VUID
N0000148510 NUI
D00804 KEGG_DRUG
4021046 VANDF
C0022322 UMLSCUI
CHEBI:6078 CHEBI
IVM PDB_CHEM_ID
CHEMBL6067487 ChEMBL_ID
D007559 MESH_DESCRIPTOR_UI
DB00602 DRUGBANK_ID
2373 IUPHAR_LIGAND_ID
4828 INN_ID
8883YP2R6D UNII
6069 RXNORM
4941 MMSL
71965 MMSL
d04101 MMSL
005266 NDDF
387559003 SNOMEDCT_US
96138006 SNOMEDCT_US
8883YP2R6D INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
STROMECTOL HUMAN PRESCRIPTION DRUG LABEL 1 0006-0032 TABLET 3 mg ORAL NDA 26 sections
SOOLANTRA HUMAN PRESCRIPTION DRUG LABEL 1 0299-3823 CREAM 10 mg TOPICAL NDA 26 sections
Ivermectin HUMAN OTC DRUG LABEL 1 0363-4230 LOTION 5 mg TOPICAL ANDA 16 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 0591-4052 CREAM 10 mg TOPICAL ANDA 26 sections
Ivermectin HUMAN OTC DRUG LABEL 1 11822-4230 LOTION 5 mg TOPICAL ANDA 16 sections
Sklice HUMAN OTC DRUG LABEL 1 24338-185 LOTION 5 mg TOPICAL NDA 16 sections
Ivermectin Human Prescription Drug Label 1 27241-293 TABLET 3 mg ORAL ANDA 11 sections
Ivermectin HUMAN OTC DRUG LABEL 1 27854-334 LOTION 5 mg TOPICAL ANDA 16 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 42799-806 TABLET 3 mg ORAL ANDA 25 sections
ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 42806-017 TABLET 3 mg ORAL ANDA 23 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 45802-102 CREAM 10 mg TOPICAL ANDA 25 sections
Ivermectin HUMAN OTC DRUG LABEL 1 46122-827 LOTION 5 mg TOPICAL ANDA 17 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5587 TABLET 3 mg ORAL ANDA 24 sections
Ivermectin HUMAN OTC DRUG LABEL 1 51316-423 LOTION 5 mg TOPICAL ANDA 16 sections
Ivermectin HUMAN OTC DRUG LABEL 1 51316-985 LOTION 5 mg TOPICAL ANDA 16 sections
Ivermectin HUMAN OTC DRUG LABEL 1 51672-4230 LOTION 5 mg TOPICAL ANDA 17 sections
STROMECTOL HUMAN PRESCRIPTION DRUG LABEL 1 55695-019 TABLET 3 mg ORAL NDA 26 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 63629-8754 CREAM 10 mg TOPICAL ANDA 25 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 68071-2242 TABLET 3 mg ORAL ANDA 25 sections
IVERMECTIN HUMAN PRESCRIPTION DRUG LABEL 1 68308-701 CREAM 10 mg TOPICAL NDA authorized generic 27 sections
ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 70771-1728 CREAM 10 mg TOPICAL ANDA 2 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 70771-1731 TABLET 3 mg ORAL ANDA 1 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 71335-2946 CREAM 10 mg TOPICAL ANDA 25 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 72162-2294 CREAM 10 mg TOPICAL ANDA 25 sections
ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 72578-120 CREAM 10 mg TOPICAL ANDA 24 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 72578-223 TABLET 3 mg ORAL ANDA 20 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 72888-206 TABLET 3 mg ORAL ANDA 11 sections
Ivermectin HUMAN PRESCRIPTION DRUG LABEL 1 72888-207 TABLET 6 mg ORAL ANDA 11 sections
BRIMONIDINE TARTRATE 0.25% / IVERMECTIN 1% / METRONIDAZOLE 1% / NIACINAMIDE 4% HUMAN PRESCRIPTION DRUG LABEL 4 72934-1028 GEL 1 g TOPICAL unapproved drug other 4 sections
IVERMECTIN 1% / METRONIDAZOLE 1% HUMAN PRESCRIPTION DRUG LABEL 2 72934-1130 GEL 1 g TOPICAL unapproved drug other 4 sections